Skip to main content
OpenTrials
Active, Not Recruiting

NCT Number: NCT05563883

Atrial Fibrillation and Cancer: a Nationwide French Cohort Study

Atrial fibrillation (AF) is a common complication associated with cancer but the risk of AF according to the cancer localization and status as well as the risk of thromboembolisms, bleedings and mortality are poorly known.

The objective of this study is to use a very large French nationwide cohort to adress thèses questions.

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Key information

Conditions

Atrial Fibrillation Arrhythmias, Cardiac Bleeding Cancer Cardiovascular Diseases Embolism and Thrombosis Heart Diseases Hemorrhage Neoplasms Pathologic Processes Pathological Conditions, Signs and Symptoms Thromboembolism Vascular Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Service de Cardiologie, Centre Hospitalier Universitaire Trousseau

Tours, 37000, France

Who can participate

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • adult hospitalized patients
  • with an ICD-10 code discharge from january 2010 to december 2019 in the French national hospital discharge database (PMSI Programme de Médicalisation des Systèmes d'Information)

Exclusion criteria

  • children

Treatment and study plan

event occurence

Other

occurence of an event of interest: (AF, cancer, thromboembolism, bleeding, mortality...

Primary outcomes

  1. atrial fibrillation

    Time frame: from inclusion in the cohort up to 10 years

    occurrence of atrial fibrillation

  2. cancer

    Time frame: ffrom inclusion in the cohort up to 10 years

    occurrence of cancer

Secondary outcomes

  1. thromboembolism

    Time frame: from inclusion in the cohort up to 10 years

    occurrence of thromboembolism

  2. bleeding

    Time frame: from inclusion in the cohort up to 10 years

    occurrence of bleeding

  3. mortality

    Time frame: from inclusion in the cohort up to 10 years

    occurrence of mortality

Sponsors and collaborators

Lead sponsor

University Hospital, Caen

Other

Collaborators

  • University Hospital, Tours

Registry information

Important dates

Study start
2022
Primary completion
2030
Study completion
2030
First posted
Oct 3, 2022
Registry last updated
Oct 3, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.